Bruker (NASDAQ:BRKR) Posts Quarterly Earnings Results

Bruker (NASDAQ:BRKR) released its quarterly earnings data on Monday. The medical research company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.33 by $0.12, Zacks reports. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the prior year, the firm earned $0.60 EPS. The business’s revenue was down .5% on a year-over-year basis. Bruker updated its FY 2025 guidance to 1.850-1.90 EPS.

Bruker Stock Performance

Bruker stock opened at $38.94 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker has a 1-year low of $28.53 and a 1-year high of $64.64. The firm has a market capitalization of $5.91 billion, a P/E ratio of 74.89, a price-to-earnings-growth ratio of 5.31 and a beta of 1.20. The company’s 50-day moving average is $34.44 and its 200 day moving average is $36.97.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, September 23rd. Bruker’s dividend payout ratio is 38.46%.

Analysts Set New Price Targets

Several research analysts have commented on BRKR shares. Wells Fargo & Company dropped their price objective on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Tuesday, August 5th. Citigroup dropped their price objective on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the company a “buy” rating in a research report on Monday, August 4th. Barclays decreased their target price on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, October 2nd. Finally, Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the company a “hold” rating in a research report on Tuesday, August 5th. Five equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bruker currently has a consensus rating of “Hold” and a consensus target price of $51.00.

Insiders Place Their Bets

In related news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director directly owned 18,016 shares of the company’s stock, valued at $581,016. This represents a 16.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.30% of the stock is owned by company insiders.

Institutional Trading of Bruker

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BRKR. EverSource Wealth Advisors LLC raised its position in Bruker by 51.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after purchasing an additional 942 shares during the period. Tower Research Capital LLC TRC raised its position in Bruker by 56.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,172 shares of the medical research company’s stock worth $172,000 after purchasing an additional 1,497 shares during the period. iSAM Funds UK Ltd purchased a new stake in Bruker in the 2nd quarter worth about $217,000. Vident Advisory LLC purchased a new stake in Bruker in the 2nd quarter worth about $251,000. Finally, Marshall Wace LLP purchased a new position in shares of Bruker during the second quarter worth approximately $252,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.